• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

When Should I feel Better After Starting PAH Treatment?

August 22, 2017 By Dr. Jeremy Feldman

pah biking

This is a very important question.   Patients with PAH are often very frustrated by feeling poorly, often for one to two years prior to formal diagnosis with PAH.  Once the secure diagnosis is made and treatment is started there is a sense of urgency for both patients and doctors to see tangible evidence of improvement.  Improvement is measured in many different ways.  You may feel less short of breath, or be able to do more.  You may feel less tired or have less chest pain. Your doctor may be able to measure improvement in exercise capacity (increased six-minute walk distance) or see improvements in your echocardiogram, heart catheterization or blood tests such as BNP.

Many of the clinical research studies showed improvements in exercise capacity that were measurable after four weeks of therapy.  Some studies required more time until benefit was seen.  Not every medication leads to improvement in all aspects of PAH.  Some lead to reduced hospitalizations while not having a dramatic impact on exercise capacity.  Others lead to increases in walk distance but patients may not report dramatic changes in symptoms.

PAH is a complex disease with many symptoms.  There are a battery of assessments including physical exam, reported symptoms, walk tests, blood tests, echocardiography, heart catheterization, and cardiac MRI that can be used to evaluate your progress.  Not every test is performed at the same frequency (or even at all).  Some centers will use echocardiography and not perform repeat heart catheterization.  Other centers will favor heart catheterization.

The important point is that frequent assessments are performed to evaluate your progress.  Patients often don’t appreciate their progress for 1-2 months.  It is common for patients to report unchanged levels of fatigue and shortness of breath with activity after starting a new therapy.  On more careful questioning, these same patients are doing much more, which explains their unchanged fatigue.  Therefore, a careful history and quantitative assessment is essential.

After 1 Month, Most PAH Patients See Improvement in Some Capacity

By one month most patients are better in some capacity after starting a new treatment.  If by three months there is no measurable improvement, then a careful re-evaluation should take place.  For newly treated patients started on PDE5 inhibitors (Tadalafil/Adcirca or Sildenafil/Revatio) and ERAs (Letairis/Ambrisentan, Opsumit/Macitentan, or Tracleer/Bosentan) lack of improvement by three months is a cause for concern.  In my experience, many of these patients that did not show any improvement never had PAH in the first place.  Across the United States, many patients are misdiagnosed as having PAH when they actually have PH due to left heart disease (usually diastolic heart failure/heart failure with preserved ejection fraction).

To learn more about failure to improve despite PAH treatment click here.  

Filed Under: Pulmonary Hypertension Treatments

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

pulmonary hypertension related lung disease

Pulmonary Hypertension and Interstitial Lung Disease

By Dr. Jeremy Feldman

Pulmonary hypertension (elevated pressure within the blood vessels of the lungs) is organized into five groups: Group

sleep apnea man

Sleep Apnea and Pulmonary Arterial Hypertension

By Dr. Jeremy Feldman

  Obstructive sleep apnea (OSA) is a very common problem.  Patients with this disorder experience repeated

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives